Human neural precursor cells express functional kappa-opioid receptors. 2007

Wen S Sheng, and Shuxian Hu, and Greg Herr, and Hsiao T Ni, and R Bryan Rock, and Genya Gekker, and James R Lokensgard, and Phillip K Peterson
The Center for Infectious Diseases and Microbiology Translational Research, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA. sheng008@umn.edu

Neural stem cells (NSCs) play an important role in the developing as well as adult brain. NSCs have been shown to migrate toward sites of injury in the brain and to participate in the process of brain repair. Like NSCs, cultured human neural precursor cells (NPCs) are self-renewing, multipotent cells capable of differentiating into neurons, astrocytes, and oligodendrocytes and of migrating toward chemotactic stimuli. Cellular and environmental factors are important for NPC proliferation and migration. Expression of kappa-opioid receptors (KORs) and mu-opioid receptors (MORs) in murine embryonic stem cells and of MORs and delta-opioid receptors in rodent neuronal precursors, as well as hippocampal progenitors has been reported by other investigators. In this study, we demonstrated robust expression of KORs in highly enriched (>90% nestin-positive) human fetal brain-derived NPCs. We found that KOR ligands, dynorphin(1-17) and trans-3,4-dichloro-N-methyl-N[2-(1-pyrolidinyl)cyclohexyl] benzeneacetamide methanesulfonate (U50,488) but not dynorphin(2-17), stimulated proliferation and migration of NPCs in a concentration-dependent manner. NPC proliferation was maximally stimulated at 10(-14) M dynorphin(1-17) and 10(-12) M U50,488. The KOR selective antagonist, nor-binaltorphimine, partially blocked the migratory and proliferative effects of KOR agonists supporting, at least in part, the involvement of a KOR-related mechanism. As has been described for rodent P19 embryonal carcinoma stem cells, retinoic acid treatment markedly suppressed KOR mRNA expression in human NPCs. Taken together, the results of this study suggest that activation of KORs alters functional properties of NPCs/NSCs that are relevant to human brain development and repair.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D012038 Regeneration The physiological renewal, repair, or replacement of tissue. Endogenous Regeneration,Regeneration, Endogenous,Regenerations
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D005333 Fetus The unborn young of a viviparous mammal, in the postembryonic period, after the major structures have been outlined. In humans, the unborn young from the end of the eighth week after CONCEPTION until BIRTH, as distinguished from the earlier EMBRYO, MAMMALIAN. Fetal Structures,Fetal Tissue,Fetuses,Mummified Fetus,Retained Fetus,Fetal Structure,Fetal Tissues,Fetus, Mummified,Fetus, Retained,Structure, Fetal,Structures, Fetal,Tissue, Fetal,Tissues, Fetal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017473 Receptors, Opioid, kappa A class of opioid receptors recognized by its pharmacological profile. Kappa opioid receptors bind dynorphins with a higher affinity than endorphins which are themselves preferred to enkephalins. Opioid Receptors, kappa,Receptors, kappa,Receptors, kappa Opioid,kappa Receptors,kappa Opioid Receptor,kappa Receptor,Opioid Receptor, kappa,Receptor, kappa,Receptor, kappa Opioid,kappa Opioid Receptors
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D053595 Embryonic Stem Cells Cells derived from the BLASTOCYST INNER CELL MASS which forms before implantation in the uterine wall. They retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells. Stem Cells, Embryonic,Cell, Embryonic Stem,Cells, Embryonic Stem,Embryonic Stem Cell,Stem Cell, Embryonic

Related Publications

Wen S Sheng, and Shuxian Hu, and Greg Herr, and Hsiao T Ni, and R Bryan Rock, and Genya Gekker, and James R Lokensgard, and Phillip K Peterson
April 2021, Neural regeneration research,
Wen S Sheng, and Shuxian Hu, and Greg Herr, and Hsiao T Ni, and R Bryan Rock, and Genya Gekker, and James R Lokensgard, and Phillip K Peterson
October 1999, Annals of the New York Academy of Sciences,
Wen S Sheng, and Shuxian Hu, and Greg Herr, and Hsiao T Ni, and R Bryan Rock, and Genya Gekker, and James R Lokensgard, and Phillip K Peterson
December 2002, Neuroreport,
Wen S Sheng, and Shuxian Hu, and Greg Herr, and Hsiao T Ni, and R Bryan Rock, and Genya Gekker, and James R Lokensgard, and Phillip K Peterson
October 2007, Anesthesia and analgesia,
Wen S Sheng, and Shuxian Hu, and Greg Herr, and Hsiao T Ni, and R Bryan Rock, and Genya Gekker, and James R Lokensgard, and Phillip K Peterson
October 2002, Immunology letters,
Wen S Sheng, and Shuxian Hu, and Greg Herr, and Hsiao T Ni, and R Bryan Rock, and Genya Gekker, and James R Lokensgard, and Phillip K Peterson
May 1994, Biochemical and biophysical research communications,
Wen S Sheng, and Shuxian Hu, and Greg Herr, and Hsiao T Ni, and R Bryan Rock, and Genya Gekker, and James R Lokensgard, and Phillip K Peterson
March 2004, Neuroreport,
Wen S Sheng, and Shuxian Hu, and Greg Herr, and Hsiao T Ni, and R Bryan Rock, and Genya Gekker, and James R Lokensgard, and Phillip K Peterson
October 1998, The Journal of pharmacology and experimental therapeutics,
Wen S Sheng, and Shuxian Hu, and Greg Herr, and Hsiao T Ni, and R Bryan Rock, and Genya Gekker, and James R Lokensgard, and Phillip K Peterson
April 2007, The Journal of pathology,
Wen S Sheng, and Shuxian Hu, and Greg Herr, and Hsiao T Ni, and R Bryan Rock, and Genya Gekker, and James R Lokensgard, and Phillip K Peterson
May 1998, European journal of pharmacology,
Copied contents to your clipboard!